Follow The Filings

BLTE Belite Bio Inc.

Health Care, filed as BELITE BIO INC (SPONSORED ADS), Equity As of 2026 Q3 so far: 135 of 140 managers we track have filed Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q3

  • 2 Owners
  • Max 0.8%
  • $122M
  • 1 add

In 2026 Q3 Lee Ainslie added to Belite Bio.

Who owns this now

Largest portfolio weights among holders, up to 0.8% (Lee Ainslie, Maverick Capital). Not free-float ownership.

  1. Lee Ainslie Add 0.81%
  2. Stanley Druckenmiller 0.40%

Who owns BLTE

Sorted by value, long equity only, as of 2026 Q3.

History
Lee Ainslie, Maverick Capital 0.81%, was 0.54% Add +53.9% 609,906 $104M History
Stanley Druckenmiller, Duquesne Family Office 0.40% Hold 106,100 $18M History

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by BLTE's executives, directors and 10% owners in the last 12 months, from their Form 4s

All BLTE insider trades
  • None no insider bought on the open market
  • $2.9M sold by 1 insider outside a trading plan
  • $38.1M sold by 5 insiders under 10b5-1 plans
  1. Hendrik Peter Scholl Chief Medical Officer
    Planned sale
    $332K 2,000 shares at $165.99 14% of stake
    Traded Nov 12 Filed Nov 16
  2. Hendrik Peter Scholl Chief Medical Officer
    Planned sale
    $83K 500 shares at $165.32 3.3% of stake
    Traded Oct 1 Filed Oct 5
  3. Yu-Hsin Lin CEO
    Planned sale
    $19.1M 100,435 shares at $190.00 59% of stake
    Traded Sep 4–8 Filed Sep 9
  4. Hao-Yuan Chuang CFO
    Planned sale
    $12.8M 67,395 shares at $189.98 72% of stake
    Traded Sep 4–8 Filed Sep 9
  5. Hao-Yuan Chuang CFO
    Planned sale
    $66K 367 shares at $180.35 0.4% of stake
    Traded Aug 12 Filed Aug 14
  6. Yu-Hsin Lin CEO
    Planned sale
    $66K 365 shares at $180.35 0.2% of stake
    Traded Aug 12 Filed Aug 14
  7. Hendrik Peter Scholl Chief Medical Officer
    Sale
    $1.5M 10,000 shares at $145.24 40% of stake
    Traded Jun 18 Filed Jun 22
  8. Hendrik Peter Scholl Chief Medical Officer
    Sale
    $1.4M 10,000 shares at $140.57 29% of stake
    Traded Jun 16 Filed Jun 17
  9. Nathan L. Mata Chief Scientific Officer
    Planned sale
    $102K 666 shares at $153.21 100% of stake
    Traded May 7 Filed May 8
  10. Nathan L. Mata Chief Scientific Officer
    Planned sale
    $154K 1,000 shares at $153.84 60% of stake
    Traded May 6 Filed May 7
  11. Nathan L. Mata Chief Scientific Officer
    Planned sale
    $156K 1,000 shares at $155.50 38% of stake
    Traded May 5 Filed May 6
  12. Nathan L. Mata Chief Scientific Officer
    Planned sale
    $156K 1,000 shares at $155.64 27% of stake
    Traded May 4 Filed May 5
  13. Nathan L. Mata Chief Scientific Officer
    Planned sale
    $156K 1,000 shares at $155.78 21% of stake
    Traded May 1 Filed May 4
  14. Nathan L. Mata Chief Scientific Officer
    Planned sale
    $157K 1,000 shares at $156.97 18% of stake
    Traded Apr 30 Filed May 1
  15. Nathan L. Mata Chief Scientific Officer
    Planned sale
    $156K 1,000 shares at $155.82 15% of stake
    Traded Apr 29 Filed Apr 30

Also filed in the last 12 months, not counted as buying or selling: 4 other transactions and 1 option exercise.

SEC filings

Recent issuer filings from EDGAR, 11 shown.

Filed Form Detail Links
6-K FORM 6-K
424B5
6-K FORM 6-K
6-K FORM 6-K
6-K FORM 6-K
6-K FORM 6-K
6-K FORM 6-K
6-K FORM 6-K
6-K FORM 6-K
SCHEDULE 13G/A —
6-K

Financials

US-GAAP annual figures, as tagged in Form 10-K

Newly public, no 10-K financials yet. See the 424B5.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf